The drug is intended to treat myopic choroidal neovascularization, a condition that can lead to vision loss or blindness.
The priority review process, which expedites the review of a drug application to about six months after filing, was created to decrease the time it takes to put new medicines on the market.
If approved, San Francisco-based Genentech would maintain all commercial rights to Lucentis in the U.S., while Roche would hold commercial rights outside the U.S.
More articles on supply chain:
St. Jude Medical issues warning on heart device after 2 patient deaths
Cost is king: 5 thoughts on the hospital supply chain from an expert who’s seen both sides of the business
Red Cross stresses need for blood, platelets after hurricane cancels 40 blood drives
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
